San Diego-based Otonomy Inc. said the U.S. Food and Drug Administration has approved Otiprio for treating a type of ear inflammation and infection in certain patients.
The drug is the first single-dose antibacterial approved by the FDA to treat the infection and inflammation of the external ear canal typically caused by a bacterial infection known as swimmer's ear, or acute otitis externa.
Otiprio has been approved by the regulatory agency to treat the condition in patients 6 months and older caused by the bacteria Pseudomonas aeruginosa and Staphylococcus aureus.
